Clinical Research Directory
Browse clinical research sites, groups, and studies.
Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin
Sponsor: Boehringer Ingelheim
Summary
To assess the influence of multiple doses of BI 425809 on single dose pharmacokinetics of midazolam (CYP3A4 probe drug), warfarin (CYP2C9 probe drug), omeprazole (CYP2C19 probe drug) and digoxin (P-gp probe drug)
Official title: A Study to Investigate the Effects of Multiple Doses of BI 425809 on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Midazolam, Warfarin and Omeprazole) and a P Glycoprotein Substrate (Digoxin) Administered Orally in an Open-label, One-sequence Trial in Healthy Male Subjects
Key Details
Gender
MALE
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
13
Start Date
2015-09-07
Completion Date
2015-10-30
Last Updated
2026-04-15
Healthy Volunteers
Yes
Conditions
Interventions
Midazolam
Warfarin
Omeprazole
Digoxin
BI 425809
Tablet
Locations (1)
1346.22.1 Boehringer Ingelheim Investigational Site
Biberach, Germany